GQ
LIVE

Serial Number

97627400

Owner

GeneQuine Biotherapeutics GmbH

Attorney

Keith Toms, Esq.

Filing Date

Oct 11, 2022

Add to watchlist:

No watchlists yet
View on USPTO

GQ Trademark

Serial Number: 97627400 • Registration: 7465095

GQ is a trademark filed by GeneQuine Biotherapeutics GmbH on October 11, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

GeneQuine Biotherapeutics GmbH

Harburger Schlossstr. 6-12
Hamburg 21079 , DE

Entity Type: 99

GQ BIO THERAPEUTICS GMBH

Ballindamm 39
HAMBURG 20095 , DE

Entity Type: 27

PACIRA GERMANY GMBH

BALLINDAMM 39
HAMBURG 20095 , DE

Entity Type: 27

Trademark Details

Filing Date

October 11, 2022

Registration Date

August 6, 2024

Published for Opposition

May 21, 2024

Goods & Services

Vaccines; Analgesic preparations; Anti-arthritic compositions and preparations; Anti-cancer preparations; Anti-inflammatory preparations; Biological preparations for the treatment of cancer; Biological preparations for the treatment of musculoskeletal, genetic, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, nephrological, hematological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, infectious, dermatological, and immune system related diseases and disorders; Biological tissue cultures for medical purposes; Biological tissue cultures for veterinary purposes; Biological skin tissues, liver tissues, and joint tissues, namely, bone, cartilage, synovium, and tendon tissues, all intended for subsequent implantation; Cells for medical or clinical use; Diagnostic agents, preparations and substances for medical purposes; Diagnostic preparations for medical or veterinary purposes; Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; Gene therapy products, namely, genetically engineered tissues for transplant purposes; Human vaccine preparations; Medicaments for promoting recovery from tendon and muscle injuries and disorders and sports related injuries; Nucleic acid sequences and chemical reagents for medical and veterinary purposes; Pain relief medication; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations for the treatment and prevention of musculoskeletal, genetic, metabolic, endocrine, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, nephrological, hematological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, infectious, dermatological, and immune system related diseases and disorders; Veterinary pharmaceutical preparations for the prevention of musculoskeletal, genetic, metabolic, endocrine, cardiovascular, pulmonary, genitourinary, oncological, hepatological, hematological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, infectious, dermatological, and immune system related diseases and disorders; Veterinary pharmaceutical preparations for the treatment of musculoskeletal, genetic, metabolic, endocrine, cardiovascular, pulmonary, genitourinary, oncological, hepatological, hematological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, infectious, dermatological, and immune system related diseases and disorders; Veterinary preparations, namely, pain relief medication; Veterinary vaccines; In vitro diagnostic preparations for medical use

Consulting services in the field of pharmaceutical research and development; Providing reagent sample testing and diagnostic services for others for scientific research purposes; Research and development in the field of genetics, gene therapy, cell therapy, vaccines, biotechnological production, non-viral and viral vector production; Pharmaceutical drug development services for prevention and treatment of musculoskeletal, genetic, ophthalmic, metabolic, endocrine, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, nephrological, hematological, respiratory, neurological, gastrointestinal, hormonal, infectious, dermatological, and immune system related diseases and disorders; Research and development in the pharmaceutical and biotechnology fields; Research and development of vaccines and medicines; Scientific research and development; Scientific research consulting in the field of genetics, gene therapy, cell therapy, vaccines, biotechnological production, and non-viral and viral vector production; Scientific research for medical purposes in the field of musculoskeletal, genetic, metabolic, endocrine, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, nephrological, hematological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, infectious, dermatological, and immune system related diseases and disorders; Scientific research in the field of genetics and genetic engineering; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy

Biomanufacturing for others, namely, manufacturing of biologics, vaccines, non-viral and viral vectors, and gene and cell therapy preparations, all using biological organisms in the manufacturing process; Custom manufacture of pharmaceuticals, biologics, vaccines, biotechnological products, non-viral and viral vectors, and gene and cell therapy preparations by pharmaceutical compounders; Custom manufacture of pharmaceuticals, biologics, vaccines, biotechnological medications, non-viral and viral vectors, and gene and cell therapy preparations; Manufacturing process consulting; Manufacturing services for others in the field of pharmaceuticals, biologics, vaccines, non-viral and viral vectors, and gene therapy and gene and cell therapy preparations; Technical support services, namely, providing technical advice related to the manufacture of biologics, gene therapy preparations, vaccines, non-viral and viral vectors

Filing History

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Dec 1, 2025 ASGN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 1, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 1, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 1, 2025 REAP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 20, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Aug 20, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 20, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 20, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 20, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 20, 2024 COAR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 6, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 6, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 21, 2024 NPUB
PUBLISHED FOR OPPOSITION
May 21, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 1, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 15, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 11, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 11, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 11, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 21, 2024 GNRN
NON-FINAL ACTION E-MAILED
Feb 21, 2024 GNRT
NON-FINAL ACTION WRITTEN
Feb 21, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 22, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 22, 2024 CRFA
ASSIGNED TO LIE
Jan 22, 2024 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 31, 2023 TROA
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 23, 2023 ASGN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 14, 2023 GNRN
NON-FINAL ACTION E-MAILED
Aug 14, 2023 GNRT
NON-FINAL ACTION WRITTEN
Aug 14, 2023 CNRT
ASSIGNED TO EXAMINER
Jul 26, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 26, 2022 NWOS
NEW APPLICATION ENTERED
Oct 14, 2022 NWAP